The canine heartworm treatment market is projected to grow from USD 4.5 billion in 2026 to USD 7.9 billion by 2036, at a CAGR of 5.8%. Macrocyclic lactone preventives will dominate with a 36.0% market share, while preventive therapy will lead the application segment with a 54.0% share.